Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its products candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The company was founded in 2007 and is headquartered in Devon, Pennsylvania.
Had this one in today's daily picks thread. Nice follow through of yesterday's breakout. Not seen on the chart above but this one has some horizontal resistance coming up at around 21 which is a spike high from March of last year.
$ZYNE The next GW Pharmaceuticals? Buy on the dip, a steal at $18 bottom price targets are $22 with a mean of $27
^^ Am sure that big red one on 1 minute was all you!!!!! Was aiming for $7 but jumped out $6.70. Done for now - off to gym
This time i was hoping for $8. but not greedy - actually chickened out In @ $6.73 out @ $7.79 & now iit's probably going to $8!
All the sudden this is on everybody watch list, 8 million tomorrow and we are back to its normal levels
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome - https://finance.yahoo.com/news/zynerba-pharmaceuticals-announces-positive-top-103000701.html